Age is a risk factor and a prognostic parameter in elderly high-grade non-Hodgkin’s lymphoma (NHL) patients. Several
Age is a risk factor and a prognostic parameter in elderly high-grade non-Hodgkin’s lymphoma (NHL) patients. Several adapted chemotherapeutic regimens have recently been designed and tested in elderly patients. Several of these trials have shown that a percentage of older high-grade NHL patients can benefit from a specific and adequate treatment in terms of cure.
Between January 1992 and September 1997, 350 previously untreated patients 60 years and older with high-grade NHL (updated Kiel classification) were treated with the VNCOP-B regimen, a MACOP-B-like scheme, consisting of mitoxantrone, 10 mg/m², and cyclophosphamide, 300 mg/m², on weeks 1, 3, 5, and 7; vincristine, 2 mg total dose, on weeks 2, 4, 6, and 8; etoposide, 150 mg/m², on weeks 2 and 6; bleomycin, 10 mg/m², on weeks 4 and 8; and prednisone, 40 mg daily with dose tapering over the last 2 weeks (Haematologica 78:378, 1993).
Of the 350 patients, 202 (58%) obtained a complete response (CR) and 87 achieved a partial response (PR), but the remaining 61 patients did not respond to therapy. The overall response rate (CR + PR) was 83%; the CR rates for three age subgroups (60 to 69, 70 to 79, and ³ 80 years) were similar: 61%, 59%, and 56%, respectively. Clinical and hematologic toxicities were irrelevant because 71% of these patients utilized granulocyte colony-stimulating factor (G-CSF, filgrastim [Neupogen]) (Blood 89:3974, 1997). At 5 years, the relapse-free survival rate was 65% and the overall survival rate was 62%.
In a multivariate analysis, prognostic factors associated with longer survival or longer relapse-free survival were: localized disease stage (P = .001) and good performance status (P = .0002). The application of the International Prognostic Factor Index was significantly associated with outcome (P = .001).
CONCLUSION: These data confirm, in a large cohort of patients, that the VNCOP-B regimen is effective in inducing a good CR with moderate toxic effects and in producing long-term relapse-free survival in elderly patients with high-grade NHL
.Click here for Dr. Bruce Cheson’s commentary on this abstract.
Oncologists Reflect on Pandemic's Lasting Impact on Cancer Care
Hear from leading cancer experts about the lasting impact the COVID-19 pandemic has left on clinical practice.